Windlas Biotech Limited (WINDLAS) - Net Assets

Latest as of September 2025: Rs5.34 Billion INR ≈ $57.76 Million USD

Based on the latest financial reports, Windlas Biotech Limited (WINDLAS) has net assets worth Rs5.34 Billion INR (≈ $57.76 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs8.14 Billion ≈ $88.05 Million USD) and total liabilities (Rs2.80 Billion ≈ $30.29 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how strategically is Windlas Biotech Limited's equity deployed to assess the company's strategic physical and investment asset allocation.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Rs5.34 Billion
% of Total Assets	65.6%
Annual Growth Rate	22.09%
5-Year Change	154.0%
10-Year Change	N/A
Growth Volatility	34.42

Windlas Biotech Limited - Net Assets Trend (2018–2025)

This chart illustrates how Windlas Biotech Limited's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Windlas Biotech Limited (WINDLAS) market capitalisation.

Annual Net Assets for Windlas Biotech Limited (2018–2025)

The table below shows the annual net assets of Windlas Biotech Limited from 2018 to 2025. Also explore Windlas Biotech Limited (WINDLAS) net asset momentum to track the company's year-over-year net asset growth rate.

Year	Net Assets	Change
2025-03-31	Rs5.06 Billion ≈ $54.70 Million	+12.41%
2024-03-31	Rs4.50 Billion ≈ $48.66 Million	+11.85%
2023-03-31	Rs4.02 Billion ≈ $43.50 Million	+1.90%
2022-03-31	Rs3.95 Billion ≈ $42.69 Million	+98.26%
2021-03-31	Rs1.99 Billion ≈ $21.53 Million	-5.03%
2020-03-31	Rs2.10 Billion ≈ $22.67 Million	+8.30%
2019-03-31	Rs1.94 Billion ≈ $20.94 Million	+54.82%
2018-03-31	Rs1.25 Billion ≈ $13.52 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Windlas Biotech Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 707.6% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (March 2025)

Component	Amount	Percentage
Retained Earnings	Rs2.75 Billion	54.36%
Common Stock	Rs104.80 Million	2.07%
Other Components	Rs2.20 Billion	43.57%
Total Equity	Rs5.06 Billion	100.00%

Windlas Biotech Limited Competitors by Market Cap

The table below lists competitors of Windlas Biotech Limited ranked by their market capitalization.

Company	Market Cap
Rithm Acquisition Corp. NYSE:RAC	$250.32 Million
QST International TWO:8349	$250.33 Million
MEDI ASSIST HEALTHCARE SERVICES LIMITED NSE:MEDIASSIST	$250.36 Million
H+H International A/S CO:HH	$250.45 Million
Brompton Split Banc Corp TO:SBC	$250.29 Million
Armada Acquisition Corp. II NASDAQ:XRPN	$250.14 Million
Meeka Metals Ltd AU:MEK	$250.13 Million
Leenos Corp KQ:039980	$250.12 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Windlas Biotech Limited's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 4,499,360,000 to 5,057,720,000, a change of 558,360,000 (12.4%).
Net income of 609,940,000 contributed positively to equity growth.
Dividend payments of 114,950,000 reduced retained earnings.
Other comprehensive income decreased equity by 189,700,000.
Other factors increased equity by 253,070,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	Rs609.94 Million	+12.06%
Dividends Paid	Rs114.95 Million	-2.27%
Other Comprehensive Income	Rs-189.70 Million	-3.75%
Other Changes	Rs253.07 Million	+5.0%
Total Change	Rs-	12.41%

Book Value vs Market Value Analysis

This analysis compares Windlas Biotech Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 4.58x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 14.46x to 4.58x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2018-03-31	Rs75.97	Rs1098.15	x
2019-03-31	Rs88.82	Rs1098.15	x
2020-03-31	Rs115.15	Rs1098.15	x
2021-03-31	Rs109.36	Rs1098.15	x
2022-03-31	Rs192.60	Rs1098.15	x
2023-03-31	Rs185.93	Rs1098.15	x
2024-03-31	Rs215.56	Rs1098.15	x
2025-03-31	Rs239.64	Rs1098.15	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Windlas Biotech Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 12.06%
The company shows good efficiency in utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 8.03%
• Asset Turnover: 1.00x
• Equity Multiplier: 1.50x
Recent ROE (12.06%) is below the historical average (12.86%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2018	8.96%	3.18%	1.21x	2.32x	Rs-13.06 Million
2019	32.97%	20.91%	1.02x	1.54x	Rs444.63 Million
2020	7.73%	4.94%	0.97x	1.61x	Rs-47.53 Million
2021	7.95%	3.71%	1.44x	1.49x	Rs-40.80 Million
2022	9.65%	8.22%	0.94x	1.24x	Rs-13.89 Million
2023	10.60%	8.35%	0.97x	1.31x	Rs23.99 Million
2024	12.93%	9.25%	1.00x	1.39x	Rs131.93 Million
2025	12.06%	8.03%	1.00x	1.50x	Rs104.17 Million

Industry Comparison

This section compares Windlas Biotech Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $28,018,515,021
Average return on equity (ROE) among peers: 13.16%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Windlas Biotech Limited (WINDLAS)	Rs5.34 Billion	8.96%	0.52x	$250.31 Million
Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS)	$354.09 Million	3.07%	2.25x	$30.30 Million
Aarti Drugs Limited (AARTIDRUGS)	$1.00 Billion	13.75%	2.66x	$420.83 Million
Aarti Pharmalabs Limited (AARTIPHARM)	$13.86 Billion	-0.01%	0.47x	$773.91 Million
Abbott India Limited (ABBOTINDIA)	$3.05 Billion	19.95%	0.50x	$6.00 Billion
Ajanta Pharma Limited (AJANTPHARM)	$25.99 Billion	18.00%	0.28x	$4.74 Billion
Akums Drugs and Pharmaceutical (AKUMS)	$33.31 Billion	7.66%	0.64x	$1.27 Billion
Alkem Laboratories Limited (ALKEM)	$12.05 Billion	19.50%	0.29x	$6.67 Billion
Amrutanjan Health Care Limited (AMRUTANJAN)	$964.67 Million	9.99%	0.49x	$153.02 Million
Alembic Pharmaceuticals Limited (APLLTD)	$50.67 Billion	22.63%	0.32x	$1.75 Billion
Aurobindo Pharma Limited (AUROPHARMA)	$138.92 Billion	17.02%	0.90x	$10.33 Billion

About Windlas Biotech Limited

NSE:WINDLAS India Drug Manufacturers - Specialty & Generic

Market Cap

$250.31 Million

Rs23.15 Billion INR

Market Cap Rank

#15731 Global

#794 in India

Share Price

Rs1098.15

Change (1 day)

-2.75%

52-Week Range

Rs718.35 - Rs1154.75

All Time High

Rs1154.75